EHA 2025

Professor Stefano Luminari

University of Modena and Reggio Emilia, AUSL IRCCS, Reggio Emilia, Italy

Stefano Luminari is Full Professor of Medical Oncology at the University of Modena and Reggio Emilia and is head of the Lymphoma research Unit of Reggio Emilia national research hospital. His research and clinical activity is mainly focussed on phase II and III clinical trials in lymphomas, biomarker and prognostic studies. He is member of the board of directors of the Fondazione Italiana Linfomi. 

 

Dr Lorenzo Falchi

Memorial Sloan Kettering Cancer Center, New York, USA

Dr. Falchi earned his MD degree Cum Laude and a board certification in Medical Oncology Cum Laude at the University of Perugia, Italy. He subsequently completed a postdoctoral fellowship at MD Anderson Cancer Center in Houston, TX, medicine residency at Yale-New Haven Hospital in New Haven, CT, and Hematology/Oncology fellowship at Columbia University Irving Medical Center in New York, NY. He is board certified in Internal Medicine, Hematology and Medical Oncology. He currently holds a dual appointment as Assistant Attending in the Lymphoma Service and Cellular Therapy Service at Memorial Sloan-Kettering Cancer Center, and is an Assistant Professor of Medicine at Weill Cornell Medical College, both in New York, NY.

Dr. Falchi’s areas of interest include non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma. His current research is focused on the use of immunotherapy for the treatment of patients with B-cell NHL through the conduct of clinical and translational studies. He is the lead investigator in multiple national and global immunotherapy trials for patients with B-cell NHL. He authored or co-authored over 70 articles published in peer-reviewed journals, including the Journal of Clinical Oncology, The Lancet Oncology, Blood, and Annals of Oncology, as well as numerous abstracts and several book chapters. 

Dr. Falchi is Co-Editor-In-Chief of Oncoimmunology, Associate Editor for Frontiers in Oncology, and member of the Editorial Board for Blood Advances and serves as peer-reviewer for numerous high-profile journals, such as JAMA, Blood and JAMA Oncology. He is recipient of several awards including the Lymphoma Research Foundation Career Development Award, and the Memorial Sloan-Kettering Steven A. Greenberg Lymphoma Research Award. He serves on multiple committees of the American Society of Clinical Oncology and Society for Immunotherapy of Cancer and is an active member of multiple scientific societies, including the American Society of Hematology, the American Society of Clinical Oncology, American Medical Association, the American Association for Cancer Research.

Dr Mary Ann Anderson

Peter MacCallum Cancer Centre, Melbourne, Australia

Associate Professor Anderson has been a practising clinical haematologist since 2012. She currently practices both at The Royal Melbourne Hospital and The Peter MacCallum Cancer Centre in Melbourne where she leads the Low-Grade Lymphoma and Chronic Lymphocytic Leukaemia Disease Stream. She is a foundation member of the CART consultant group at the Peter MacCallum Cancer Centre having joined the team at the inception of the unit in 2019. Dr Anderson obtained her PhD from the University of Melbourne in 2017 where she undertook extensive clinical and laboratory studies of a novel approach to treating B cell malignancies by harnessing apoptotic cell death with the agent now known as venetoclax. Since completion of her PhD Dr Anderson has continued her studies into mechanisms by which B cell malignancies evade targeted agents to develop therapeutic resistance.

Dr Martina Pennisi

Istituto Nazionale dei Tumori, Milan, Italy

Dr. Pennisi graduated in Hematology in 2018 at the University of Milan. During 2019-2020 she worked as post-doc research fellow at Memorial Sloan Kettering Cancer Center in New York. She has been working in the Hematology Division at Fondazione IRCCS Istituto Nazionale dei Tumori of Milan since 2017, and in the inpatient ward since 2020. Her clinical and scientific interest focuses on immune and cellular therapies, including Chimeric Antigen Receptor T cells for the treatment of patients with lymphoma and myeloma and Allogeneic Stem Cell Transplantation.

Professor Benedetto Bruno

Università di Torin, Torino, Italy

Benedetto Bruno, MD, PhD, is Associate Professor of haematology at the Department of Molecular Biotechnology and Health Sciences – School of Medicine - University of Turin, Italy - and Program Head at the Bone Marrow Transplantation Unit of the A.O.U. Città della Salute e della Scienza di Torino, Presidio Molinette, Turin, Italy. Following medical training at the University of Pavia, Italy, Dr Bruno worked as a resident in haematology at the University of Turin before taking up, in 1995, a fellowship at the Department of Transplantation Biology at the Fred Hutchinson Cancer Research Centre, Seattle, WA, USA. He passed the United States Medical License Examination in 1996. He then returned to Italy in 2000 when he received a doctorate in experimental haematology from the University of Genoa. Dr. Bruno has a particular interest in the role of autologous and allogeneic stem cell transplantation, and cell therapies in the treatment of haematological disorders, Dr. Bruno has received several awards, including the International Cancer Technology Transfer Award from the International Union Against Cancer, Geneva, Switzerland.

Dr. Noopur Raje

Harvard University, Boston, MA, USA

Noopur Raje, MD, is the Director of the Centre for Multiple Myeloma in the Mass General Cancer Centre. Dr Raje earned her MD from BJ Medical College, University of Pune in Pune, Maharashtra, India. After completing her residency at Mass General and a fellowship at Dana-Farber Cancer Institute, she returned to Mass General where she established her own lab to investigate multiple myeloma. Her lab comprises a translational research program to evaluate new therapies with a focus on myeloma bone disease biology. Dr Raje's work explores the bone marrow microenvironment and new targets for treatments that will stop tumour growth. Her research also strives to understand the factors that cause bone disease in patients with myeloma. Dr Raje is a member of the International Myeloma Working Group and National Comprehensive Cancer Network(NCCN) Clinical Practice Guidelines Committee for Multiple Myeloma. In 2010, she received the Clafin Distinguished Scholar award at Mass General. In 2013, she was named the first incumbent of the Rita M Kelley Chair in Oncology at Mass General. In 2017, she received the Leukaemia and Lymphoma Society Clinical Scholar Award. 

Dr. Doris Hansen

Moffitt Cancer Center, Tampa, FL, USA

Dr. Hansen is an Assistant Member/Professor in the Department of Blood and Marrow Transplant and Cellular Immunotherapy, and a practicing haematologist integrated in the Immune Cell Therapy (ICE-T) Program at Moffitt Cancer Centre and the University of South Florida/Morsani College of Medicine. Her clinical and research interests include utilizing autologous transplantation and cellular immunotherapies to treat and improve outcomes for patients with multiple myeloma. Dr. Hansen’s research interest focuses on characterizing both clinical and patient-reported outcomes among individuals with multiple myeloma receiving immunotherapies, as well as identifying the impact of inflammation and immunity on 
toxicity and efficacy in this patient population. 

Professor Aurore Perrot

Université de Toulouse, Toulouse, France

Aurore Perrot, MD, PhD, is an Associate Professor in Haematology at the University of Toulouse, France. Dr Perrot received her medical degree from the Henri Poincaré University, Nancy, France, in 2009 and completed her PhD at the University of Lorraine, Lorraine, France, in 2015. Dr Perrot then served as an MCU-PH at the University of Lorraine until 2019. Dr Perrot specialises in the treatment of patients with newly diagnosed multiple myeloma. Dr Perrot has been involved in a number of clinical trials investigating novel antibody therapies for multiple myeloma treatment in addition to genomics studies researching predictive markers which are significant in the treatment of multiple myeloma.